Jane Street’s Enanta Pharmaceuticals ENTA Stock Holding History

Jane Street’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-9,000	Closed	-$1.04M	–	5228
2018 Q2	$1.04M	Buy	+9,000	New	+$898K	﹤0.01%	2691

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street's ENTA Position: Q4 2025 in Review

Jane Street sold out of Enanta Pharmaceuticals (ENTA) in Q4 2025, closing a stake of 19,165 shares — an estimated $229K sold.

Jane Street first reported a position in ENTA in Q2 2014 and held it in 22 quarters. The position peaked at $1.61M in Q3 2023. 132 funds tracked by Wall St. Rank hold ENTA as of Q4 2025.

Jane Street reported no remaining Enanta Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Jane Street sold 19,165 Enanta Pharmaceuticals shares in Q4 2025, an estimated $229K.
Jane Street first reported a position in Enanta Pharmaceuticals in Q2 2014 and held it in 22 quarters.
Jane Street's Enanta Pharmaceuticals position peaked at $1.61M in Q3 2023.
132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.